Primus Capital, a private equity firm, led a $40m Series B round in PurpleLab, a health tech company, with participation from Edison Partners. “We’re laser focused on creating infrastructure and tools to assist our clients in converting real-world data into real-world evidence and this investment will accelerate the rate of adoption, conversion and ultimate return on their investment. Understanding comparative performance of various treatments for every condition is becoming easier through technologies such as deidentification via tokenization and is being further driven by legislative mandates such as the 21st Century Cures Act. In a world with increased access to RWD, the biggest challenge lies in the ability to readily interpret the data. PurpleLab’s HealthNexus™ platform was designed to solve this problem and we are thrilled that Primus shares our vision," Mark Brosso, PurpleLab CEO and Founder.